Wessex AHSN is supporting start-up MedEngine to develop and test its Flytta system, which seeks to improve self-management and clinical care in Parkinson’s Disease, a condition with few technological innovations available to help.

Find your nearest AHSN

By MedEngine


Parkinson’s Disease is the second most-common neurodegenerative disease. MedEngine have developed Flytta, a wearable device linked with a mobile app designed to closely monitor Parkinsonian symptoms to facilitate clinical care and support with tailored information.  Following successful application to Wessex AHSN’s Technology Support Programme, MedEngine is being supported to develop its product to meet the needs of patients and NHS services and undertake a trial to test its value.

How did the Innovation Exchange help?

Following successful interviews with the Technology Support Programme panel, MedEngine entered a research collaboration with Wessex AHSN. The company, initially based in Germany, will incorporate in the UK to invest in this research.

Impact & Outcomes

Wessex AHSN:

  • Made connections between innovators and an area of clinical need
  • Initiated a long-term research partnership between the innovator and clinicians
  • Facilitated MedEngine to gain insights into the NHS market from clinical sites, enabling the innovator to better understand the potential value of their system to the NHS
  • Facilitated forums for MedEngine to seek NHS user input into the design and usability of their system and its clinical reporting